$MOR News
Last published 1d ago
- 1d agoMORWOLFE RESEARCH HEALTHCARE CONFERENCE 2026 - MORPHOSYS AGEarnings Call TranscriptsGood morning everybody, my name is Andy Chen, one of the Smith Biotech analysts here at Wolf Research, and today we have Insight, we have Bill and Pablo from Insight joining us. We're very excited, and maybe starting fro
- 1w agoMORIncyte Corp. Third Quarter 2026 Earnings Call - MORPHOSYS AGEarnings Call TranscriptsGreetings and welcome to the Insight third quarter 2026 earnings call. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. You may be placed into que
- 2w agoMORINCYTE INVESTOR EVENT AT ESMO 2026 - MORPHOSYS AGEarnings Call TranscriptsGood evening, everybody, those of you here in Madrid. It's been a wonderful ESMO for us at Insight, and we're really excited about telling you a lot of the progress we're making in solid tumors. So thank you very much fo
- 2w agoMORINCYTE INVESTOR EVENT AT ESMO 2026 - MORPHOSYS AGEarnings Call TranscriptsGood evening, everybody, those of you here in Madrid. It's been a wonderful ESMO for us at Insight, and we're really excited about telling you a lot of the progress we're making in solid tumors. So thank you very much fo
- 2w agoMORINCYTE INVESTOR EVENT AT ESMO 2026 - MORPHOSYS AGEarnings Call TranscriptsGood evening, everybody, those of you here in Madrid. It's been a wonderful ESMO for us at Insight, and we're really excited about telling you a lot of the progress we're making in solid tumors. So thank you very much fo
- 1mo agoMORMorgan Stanley 24th Annual Global Healthcare Conference - MORPHOSYS AGEarnings Call TranscriptsAll right, welcome everyone to this session of the Morgan Stanley Global Healthcare Conference. I'm Judah Fromer, one of the SMIT biotech analysts here. We're very excited to have insight for this session represented by
- 1mo agoMORMorgan Stanley 24th Annual Global Healthcare Conference - MORPHOSYS AGEarnings Call TranscriptsAll right, welcome everyone to this session of the Morgan Stanley Global Healthcare Conference. I'm Judah Fromer, one of the SMIT biotech analysts here. We're very excited to have insight for this session represented by
- 2mo agoMORWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - MORPHOSYS AGEarnings Call TranscriptsAll right. Good morning, everyone. Thanks for joining us for the next Fireside Discussion. My name is Derek Archula. I'm one of the senior biotech analysts here at Wells. I'm very excited to have the next company here, I
- 11mo agoMORMORPHOSYS AG - Appeal, AffirmedUS Patent Trial and Appeal Board
- 2y agoMORMerger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General MeetingACCESS NewswireMUNICH, GERMANY / ACCESSWIRE / August 27, 2024 / MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company's Management Board and Supervisory Board at its 2024 Annual General
- 2y agoMORMorphoSys Announces Voluntary Delisting from the Nasdaq Global MarketBusiness WireMorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares ("ADSs") from the Nasdaq Global Market and
- 2y agoDMSHCRMORALEKuehn Law Encourages DM, SHCR, MOR, and ALE Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoMORMorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority ShareholdersBusiness WireMorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by
- 2y agoMORAd hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG's Minority ShareholdersACCESS NewswirePLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as
- 2y agoMORMorphoSys AG Reports First Quarter 2024 Financial ResultsBusiness Wire– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion – Received all mandatory antitrust approvals for the proposed
- 2y agoMORMorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by NovartisACCESS NewswireNovartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billionShareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last
- 2y agoMORMorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by NovartisBusiness WireNovartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and
- 2y agoMORMorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR ActACCESS NewswirePLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the
- 2y agoMORMorphoSys AG (MOR) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoMORMorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateBusiness Wire– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash or € 2.7 billion equity value – Sold all tafasitamab rights worldwide to Incyte – Presented comprehensive Phase
- 2y agoMORInvitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024ACCESS NewswireConference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT;
- 2y agoMORMorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity ValueACCESS NewswireTafasitamab sold to IncyteNovartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cashShareholders benefit from attractive premium of 94 percent to the
- 2y agoINCYMORIncyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)Business Wire– Tafasitamab is approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and is currently in Phase 3 trials for multiple indications Incyte
- 2y agoMORMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial LiabilityACCESS NewswirePreliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million and preliminary gross margin for Monjuvi U.S. net product sales of 69%Anticipated 2024 Monjuvi U.S. net product sales in the
- 2y agoMORMorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceACCESS NewswirePLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 8, 2024 / MorphoSys AG today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare
- 2y agoMORMorphoSys' Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 StudyBusiness WirePelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib Showed a strong positive trend in reducing symptom burden and a
- 2y agoMORAd hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom ReductionACCESS NewswirePublication of an inside information according to Article 17 para. 1 of the Regulation No. 596/2014MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate The key secondary endpoints
- 2y agoMORMorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom ReductionBusiness WireMANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%) The key secondary endpoints assessing symptom reduction, TSS50 and absolute change in TSS, showed significant improvements for
- 2y agoMORMorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial ResultsBusiness Wire– Phase 3 MANIFEST-2 topline results expected by the end of November, with detailed findings in oral presentation at ASH 2023 – Monjuvi® U.S. net product sales of US$ 23.4 million (€ 21.5 million) for the third
- 3y agoMORInvitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023ACCESS NewswireConference Call AlertPLANEGG and MUNICH, GERMANY / ACCESSWIRE / November 9, 2023 / MorphoSys AG will publish its results for the third quarter and first nine months 2023 on November 15, 2023, at
- 3y agoMORMorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual MeetingACCESS NewswireFollowing topline results expected in the coming weeks, the oral session at ASH 2023 in December will provide detailed findings from MANIFEST-2Investor event focused on MANIFEST-2 with MorphoSys management and medical
- 3y agoMORMorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023ACCESS NewswirePreliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65%Anticipate full year 2023 Monjuvi U.S. net
- 3y agoMORMorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial CancerACCESS NewswireTulmimetostat follows pelabresib and tafasitamab as the company's third clinical program to receive Fast Track designationPLANEGG and MUNICH, GERMANY / ACCESSWIRE / September 12, 2023 / MorphoSys AG
- 3y agoMORMorphoSys AG Reports Second Quarter and First Half 2023 Financial ResultsBusiness Wire– Monjuvi® U.S. net product sales of US$ 23.6 million (€ 21.7 million) for the second quarter of 2023 – Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline
- 3y agoMORMorphoSys AG Reports First Quarter 2023 Financial ResultsBusiness Wire– Monjuvi® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 – Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline
- 3y agoMORMorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateBusiness Wire– Topline data from the Phase 3 MANIFEST-2 study expected in early 2024 – Monjuvi® U.S. net product sales of US$ 25.3 million (€ 24.7 million) for the fourth quarter of 2022 and US$ 89.4 million (€ 84.9 million)
- 3y agoPFEMORINCYEffects of PF-07901801,Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma - NCT05626322ClinicalTrials.govPhase 1b: Dose limiting toxicity (DLT) rate, Phase 2: Objective Response (OR), Phase 1b and Phase 2: Frequency of adverse events (AE), (and 13 more...)
- 3y agoMORMorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial ResultsBusiness Wire– Monjuvi® U.S. net product sales of US$ 22.2 million (€ 21.9 million) for the third quarter of 2022 – Presentation of preliminary results from phase 1/2 study of tulmimetostat (CPI-0209) supporting its potential
- 4y agoMORTEVACARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory AffairsPR NewswireSHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors,
- 4y agoMORMorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCLBusiness WireThe findings, including data from patients treated with the targeted immunotherapy for 5 years or more, will be presented during the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022) MorphoSys U.S. Inc., a fully owned subsidiary
- 4y agoMORMorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte PetersBusiness WireTim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology MorphoSys AG ((FSE: MOR, NASDAQ:MOR) announced today that Malte Peters, M.D., the company's Chief Research and Development Of
- 4y agoMORMorphoSys AG (MOR) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsMOR earnings call for the period ending June 30, 2022.
- 4y agoMORMPSYFMorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022ACCESS NewswireConference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 28, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 pm BST; 4:00
- 4y agoMORMPSYFMorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022ACCESS NewswirePreliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million) Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million) Update of R&D expense guidance (now € 275 to € 300
- 4y agoMORMPSYFMorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022ACCESS NewswirePublication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million) Update of financial guidance ranges for 2022 Monjuvi U.S
- 4y agoIMABMORI-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210PR NewswireSHANGHAI and GAITHERSBURG, Md., June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ:IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets th
- 4y agoMORMorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210Business WireHuman Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital HIBio obtains exclusive worldwide rights, with t
- 4y agoINCYMORPFEPfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47Business WirePfizer Inc. (NASDAQ:PFE), MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG ((FSE: MOR, NASDAQ:MOR), and Incyte (NASDAQ:INCY) today announced a clinical trial collaboration and supply agreement to investigate the immunotherapeutic combinatio
- 4y agoMORMorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022Business WireNew translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and ruxolitinib-relapsed/refractory patients A comparative model suggests an improvement in SVR35 and TSS50 in JAK inhibitor-na
- 4y agoMORMPSYFMorphoSys AG Reports Outcome of Annual General Meeting 2022ACCESS NewswirePLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual Genera